From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Trade namesMyrbetriq, Betanis, Betmiga, others
Other namesYM-178
License data
  • AU: B3
  • US: C (Risk not ruled out)
Routes of
By mouth (tablets)
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding71%[1]
MetabolismHepatic via (direct) glucuronidation, amide hydrolysis, and minimal oxidative metabolism in vivo by CYP2D6 and CYP3A4. Some involvement of butylcholinesterase[1]
Elimination half-life50 hours[1]
ExcretionUrine (55%), faeces (34%)[1]
CAS Number
PubChem CID
ECHA InfoCard100.226.392 Edit this at Wikidata
Chemical and physical data
Molar mass396.506 g/mol g·mol−1
3D model (JSmol)

Mirabegron, sold under the brand name Myrbetriq among others, is a medication used to treat overactive bladder.[2] Its benefits are similar to other antimuscarinic medication such as solifenacin or tolterodine.[3] In the United Kingdom it is less preferred to antimuscarinic medication such as oxybutynin.[4] It is taken by mouth.[2]

Common side effects include high blood pressure, headaches, and urinary tract infections.[2] Other significant side effects include urinary retention, irregular heart rate, and angioedema.[2][4] It works by activating the β3 adrenergic receptor in the bladder, resulting in its relaxation.[4][2]

Mirabegron was approved for medical use in the United States in 2012.[5][2] A month supply in the United Kingdom costs the NHS about £29 as of 2019.[4] In the United States the wholesale cost of this amount is about 369 USD.[6] In 2016 it was the 263rd most prescribed medication in the United States with more than a million prescriptions.[7]

Medical uses[edit]

Myrbetriq 50 mg both sides

Its used is in the treatment of overactive bladder.[1][8][9] It works equally well to antimuscarinic medication such as solifenacin or tolterodine.[3] In the United Kingdom it is less preferred to these agents.[4]

Adverse effects[edit]

Adverse effects by incidence:[1][8][9]

Very common (>10% incidence) adverse effects include:

Common (1–10% incidence) adverse effects include:

Rare (<1% incidence) adverse effects include:


Myrbetriq is pronounced /mɪərˈbɛtrɪk/ meer-BET-rik.


  1. ^ a b c d e f g "mirabegron (Rx) - Myrbetriq". Medscape Reference. WebMD. Retrieved 17 November 2013.
  2. ^ a b c d e f "Mirabegron Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 18 March 2019.
  3. ^ a b "[93] Are claims for newer drugs for overactive bladder warranted?". Therapeutics Initiative. 22 April 2015. Retrieved 17 March 2019.
  4. ^ a b c d e British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 763. ISBN 9780857113382.
  5. ^ Sacco, E; Bientinesi, R; et al. (Apr 2014). "Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence". Expert Opin Drug Discov. 9 (4): 433–48. doi:10.1517/17460441.2014.892923. PMID 24559030.
  6. ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
  7. ^ "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.
  8. ^ a b "MYRBETRIQ (mirabegron) tablet, film coated, extended release [Astellas Pharma US, Inc.]". DailyMed. Astellas Pharma US, Inc. September 2012. Retrieved 17 November 2013.
  9. ^ a b "Betmiga 25mg & 50mg prolonged-release tablets". electronic Medicines Compendium. Astellas Pharma Ltd. 22 February 2013. Retrieved 17 November 2013.

External links[edit]